Correction to: Leukemia (2008) 22, 1925–1932; doi:10.1038/leu.2008.174; published online 3 July 2008
Owing to a typesetting error, Figure 2b of the above article was published incorrectly.
Effect of lenalidomide and bortezomib on transcription factors during osteoclastogenesis. (a) Lenalidomide (100% at 0 μM, 60.2% at 2 μM and 48.8% at 10 μM), but not bortezomib, resulted in a dose-dependent inhibition of extracellular signal-regulated kinase (ERK) phosphorylation in peripheral blood mononuclear cells (PBMCs) incubated with macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) for 3 h. (b) Lenalidomide, but not bortezomib, resulted in a decrease of PU.1 after incubation of PBMCs for 4 days in the presence of RANKL and M-CSF. Conversely, bortezomib, but not lenalidomide, downregulated NFATc1. C-fos was not downregulated by either agent at 5 days.
The correct figure is reproduced here.
The publisher apologizes for this error and any inconvenience it may have caused.
Additional information
The online version of the original article can be found at 10.1038/leu.2008.174
Rights and permissions
About this article
Cite this article
Breitkreutz, I., Raab, M., Vallet, S. et al. Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22, 1973 (2008). https://doi.org/10.1038/leu.2008.216
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.216
This article is cited by
-
An Evidence-Based Approach to Myeloma Bone Disease
Current Hematologic Malignancy Reports (2017)
